Lumida
/TEVA
⌘K
Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd

TEVA
$32.03USD↓-0.59%-0.19 today

MARKET CAP

33.0B

P/E (TTM)

10.9x

FWD P/E

12.9x

DAY RANGE

$32 – $33

52W RANGE

$15
$37

AI Summary

Stalk
TrimMedium

TEVA remains in a Stage 4 decline with confirmed lower highs and lower lows under downward‐sloping EMAs. Medium‐term bias is bearish, but price is extreme oversold and trading below the 9/21/50 EMA cluster, making immediate sell entries unattractive. We will defer execution and stalk for a bounce into the EMA resistance zone, offering a higher‐probability setup to trim positions.

  • ↑Q1 revenue $4B (+4% YoY; +7% ex-divestments).
  • ↑Adjusted EBITDA +7% YoY; non-GAAP EPS +10% YoY.
  • ↓Shares trade ~64% above GF Value; weak book-to-price and dividend yield.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Teva Pharmaceutical Industries Limited (NYSE: TEVA) is a leading global pharmaceutical company primarily engaged in the development, production, and marketing of generic and specialty medications. The company's strategic focus is shifting from a reliance on generics towards a more diversified biopharmaceutical portfolio, emphasizing innovative therapies. This transition aims to address significant unmet medical needs, particularly in areas such as central nervous system disorders and autoimmune diseases. Teva is now recognized as a player in the growing market of biopharmaceuticals, reflecting a thematic shift in the broader pharmaceutical landscape.

Bull says

  • ↑Q1 revenue $4B (+4% YoY; +7% ex-divestments).
  • ↑Adjusted EBITDA +7% YoY; non-GAAP EPS +10% YoY.
  • ↑Free cash flow rose 76% to $200M.
  • ↑Innovative drugs like Esteto grew 38% YoY.
  • ↑Transformation program targets $700M savings by 2027; strong profitability and momentum factors support margins.
  • ↑Upcoming filings (olanzapine LAI, dual-action inhaler) serve as catalysts.

Bear says

  • ↓Shares trade ~64% above GF Value; weak book-to-price and dividend yield.
  • ↓High short interest underscores market skepticism.
  • ↓Generics revenue set to decline sharply in 2026 cliff.
  • ↓Heavy reliance on new drug approvals; delays risk revenue.
  • ↓Ambitious biopharma pivot adds execution and balance-sheet risks.
  • ↓Pricing negotiations and legal settlement risks threaten cash flow.

Investment themes with TEVA

International Value↑ +0.73%

Value-oriented stocks outside domestic markets

HSBA.L · BATS.L · 7203.T

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-09-2026neutral

Transcript signals

Bull points

  • we're very excited about this future potential for our pipeline
  • We just did our EU submission just yesterday, and we'll be looking forward to the validation of that acceptance by the EU in the coming months
  • we've now completed the enrollment of the large phase three program called FLARE, enrolling over 2,700 patients, including a very substantial sample size of both pediatrics and adolescents, which is crucial since 25% of asthma patients are within these demographics

Bear points

  • Non-GAAP operating margin decreased approximately 50 basis points year over year to 24%, mainly due to higher planned investment in sales and marketing to support our innovative growth.
  • We also expected approximately $75 million of additional operating expenses in 2026 related to MLX starting Q3, including the transaction costs.
  • we expected our operating expenses for 2026 to be towards the higher end of our 27 to 28% range.
Read full transcript analysis ›